Palisade Bio Secures $1.5M Convertible Note Financing
Ticker: PALI · Form: 8-K · Filed: May 3, 2024 · CIK: 1357459
| Field | Detail |
|---|---|
| Company | Palisade Bio, Inc. (PALI) |
| Form Type | 8-K |
| Filed Date | May 3, 2024 |
| Risk Level | medium |
| Pages | 5 |
| Reading Time | 6 min |
| Key Dollar Amounts | $0.01, $6.5015, $4.0 m, $0.0001, $6.314 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financing, debt-financing, convertible-note
TL;DR
Palisade Bio just raised $1.5M via a convertible note, potentially funding their pipeline.
AI Summary
On May 1, 2024, Palisade Bio, Inc. entered into a Material Definitive Agreement, specifically a Convertible Promissory Note Purchase Agreement with an investor. The agreement involves the issuance of a convertible promissory note with a principal amount of $1,500,000. This transaction is part of the company's ongoing efforts to secure financing.
Why It Matters
This financing provides Palisade Bio with crucial capital, potentially enabling them to advance their drug development programs and operations.
Risk Assessment
Risk Level: medium — Convertible notes can dilute existing shareholders if converted, and the company's ability to repay or convert depends on future performance.
Key Numbers
- $1.5M — Convertible Promissory Note Principal (Financing secured by Palisade Bio)
Key Players & Entities
- Palisade Bio, Inc. (company) — Registrant
- May 1, 2024 (date) — Date of earliest event reported
- $1,500,000 (dollar_amount) — Principal amount of convertible promissory note
- Convertible Promissory Note Purchase Agreement (agreement) — Material Definitive Agreement
FAQ
What is the interest rate on the convertible promissory note?
The filing does not specify the interest rate on the convertible promissory note.
What is the maturity date of the convertible promissory note?
The filing does not specify the maturity date of the convertible promissory note.
What are the terms for conversion of the promissory note into equity?
The filing does not detail the specific conversion terms of the promissory note.
Who is the investor purchasing the convertible promissory note?
The filing refers to an 'investor' but does not name the specific entity.
What is the intended use of the $1.5 million in proceeds?
The filing states the proceeds are for general corporate purposes but does not provide specific allocation details.
Filing Stats: 1,423 words · 6 min read · ~5 pages · Grade level 12.5 · Accepted 2024-05-03 16:56:44
Key Financial Figures
- $0.01 — ch registered Common Stock, par value $0.01 per share PALI Nasdaq Capital Mark
- $6.5015 — price per Share or Prefunded Warrant of $6.5015 (less the applicable exercise price of
- $4.0 m — roceeds to the Company of approximately $4.0 million, before deducting fees payable to
- $0.0001 — a perpetual term, an exercise price of $0.0001 per share of Common Stock, and is subje
- $6.314 — Warrants will have an exercise price of $6.314 per share of Common Stock and a term of
- $75,000 — f the securities, (ii) payment of up to $75,000 for certain expenses incurred in the Of
- $10.727 — price of the Placement Agent Warrant is $10.727 per share and the term is five (5) year
Filing Documents
- form8-k.htm (8-K) — 56KB
- ex4-1.htm (EX-4.1) — 123KB
- ex4-2.htm (EX-4.2) — 125KB
- ex4-3.htm (EX-4.03) — 122KB
- ex10-1.htm (EX-10.1) — 261KB
- ex10-2.htm (EX-10.2) — 185KB
- ex10-3.htm (EX-10.3) — 72KB
- ex99-1.htm (EX-99.1) — 15KB
- ex99-1_001.jpg (GRAPHIC) — 2KB
- 0001493152-24-017739.txt ( ) — 1321KB
- pali-20240503.xsd (EX-101.SCH) — 3KB
- pali-20240503_lab.xml (EX-101.LAB) — 33KB
- pali-20240503_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized. Date: May 3, 2024 Palisade Bio, Inc. By: /s/ J.D. Finley J.D. Finley Chief Executive Officer